A phase II study of lipoplatin (liposomal cisplatin)/vinorelbine combination in HER-2/neu–negative metastatic breast cancer
Background Liposomal cisplatin (lipoplatin) has a mechanism of action similar to that of
cisplatin, with reduced toxicities and enhanced or similar efficacy. We wanted to assess the
efficacy and safety of a lipoplatin/vinorelbine combination in a phase II clinical trial in
metastatic breast cancer (MBC). Methods Thirty-five patients with HER-2/neu–negative
(HER-2/neu–) MBC were enrolled. Lipoplatin 120 mg/m 2 (days 1, 8, and 15) and
vinorelbine 30 mg/m 2 (days 1 and 8) were administered in a 21-day cycle. Results Thirty …
cisplatin, with reduced toxicities and enhanced or similar efficacy. We wanted to assess the
efficacy and safety of a lipoplatin/vinorelbine combination in a phase II clinical trial in
metastatic breast cancer (MBC). Methods Thirty-five patients with HER-2/neu–negative
(HER-2/neu–) MBC were enrolled. Lipoplatin 120 mg/m 2 (days 1, 8, and 15) and
vinorelbine 30 mg/m 2 (days 1 and 8) were administered in a 21-day cycle. Results Thirty …
以上显示的是最相近的搜索结果。 查看全部搜索结果